Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware… Read more
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) - Total Assets
Latest total assets as of September 2025: CN¥6.10 Billion CNY
Based on the latest financial reports, Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) holds total assets worth CN¥6.10 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A - Total Assets Trend (2011–2024)
This chart illustrates how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's total assets of CN¥6.10 Billion consist of 36.4% current assets and 63.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.5% |
| Accounts Receivable | CN¥773.56 Million | 11.7% |
| Inventory | CN¥82.30 Million | 1.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥17.30 Million | 0.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's current assets represent 36.4% of total assets in 2024, a decrease from 77.1% in 2011.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2024, down from 32.1% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 11.7% of total assets.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Competitors by Total Assets
Key competitors of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Wuhan Easy Diagnosis Biomedicine Co Ltd Class A generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Wuhan Easy Diagnosis Biomedicine Co Ltd Class A generates $ 1.13 in net profit.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.95 | 3.29 | 3.94 |
| Quick Ratio | 15.61 | 3.10 | 3.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.45 Billion | CN¥ 1.48 Billion | CN¥ 908.68 Million |
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.77 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -10.7% |
| Total Assets | CN¥6.59 Billion |
| Market Capitalization | $288.07 Million USD |
Valuation Analysis
Below Book Valuation: The market values Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's assets decreased by 10.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2024)
The table below shows the annual total assets of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.59 Billion | -10.74% |
| 2023-12-31 | CN¥7.39 Billion | -19.63% |
| 2022-12-31 | CN¥9.19 Billion | +168.97% |
| 2021-12-31 | CN¥3.42 Billion | +139.52% |
| 2020-12-31 | CN¥1.43 Billion | +123.46% |
| 2019-12-31 | CN¥638.42 Million | +3.45% |
| 2018-12-31 | CN¥617.15 Million | +140.57% |
| 2017-12-31 | CN¥256.54 Million | +30.13% |
| 2016-12-31 | CN¥197.15 Million | +47.17% |
| 2015-12-31 | CN¥133.96 Million | +119.56% |
| 2014-12-31 | CN¥61.01 Million | +156.45% |
| 2013-12-31 | CN¥23.79 Million | +410.85% |
| 2012-12-31 | CN¥4.66 Million | +137.91% |
| 2011-12-31 | CN¥1.96 Million | -- |